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ed April 16, 2013.his study sought to assess the inﬂuence of chronic kidney disease (CKD) classiﬁcation on clinical outcomes in
patients undergoing transcatheter aortic valve implantation (TAVI).Background The prognostic value of impaired renal function according to CKD classiﬁcation has not been thoroughly investigated
in very elderly TAVI cohorts.Methods Data from 642 consecutive patients who underwent TAVI were prospectively collected. Clinical outcomes were
compared in enrolled patients, divided into CKD stage 1þ2, CKD stage 3a, CKD stage 3b, and CKD stage 4 on the
basis of estimated glomerular ﬁltration rate 60, 45 to 59, 30 to 44, and 15 to 29 ml/min/1.73 m2, respectively.Results Among the study patients (mean age: 83.5  6.5 years, logistic European System for Cardiac Operative Risk
Evaluation score 20.0% [range: 13.6% to 28.8%]), 34% were categorized as CKD stage 1þ2 (n ¼ 218), 28.3% as
CKD stage 3a (n ¼ 182), 28.2% as CKD stage 3b (n ¼ 181), and 9.5% as CKD stage 4 (n ¼ 61). Thirty-day and
cumulative 1-year mortality rates increased signiﬁcantly across the 4 groups (6.9% vs. 8.8% vs. 13.3% vs. 26.2%,
p ¼ 0.002, and 17.2% vs. 23.4% vs. 29.2% vs. 47.8%, p < 0.001, respectively). After adjustment for considerable
inﬂuential confounders in a Cox multivariate regression model, CKD stage 4 was associated with increased risk for
30-day mortality (hazard ratio: 3.04; 95% conﬁdence interval [CI]: 1.43 to 6.49; p ¼ 0.004), and CKD stages 3b and
4 were related to increased cumulative 1-year mortality (hazard ratios: 1.71 and 2.91; 95% CI: 1.09 to 2.68 and
1.73 to 4.90; p ¼ 0.020 and p < 0.001, respectively) compared with CKD stage 1þ2 as the referent.Conclusions Classiﬁcation of CKD stages before TAVI allows risk stratiﬁcation for early and midterm clinical outcomes. TAVI for
patients with CKD stage 4 is still considered challenging because of high mortality rates after the procedure. (J Am
Coll Cardiol 2013;62:869–77) ª 2013 by the American College of Cardiology FoundationSee page 878Ten years after its ﬁrst introduction in the clinical ﬁeld,
transcatheter aortic valve implantation (TAVI) has now
become an innovative alternative procedure that enables
catheter-based treatment in patients considered high-risk
candidates for surgical aortic valve replacement (SAVR)
(1–3). Several studies have identiﬁed factors associated with
poor outcomes after TAVI (4–8). Impaired renal function istional Cardiology, AP-HP, Henri Mondor
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, 2012; revised manuscript received April 10,widely known to be one of the worst prognostic factors
among patients who undergo SAVR (9,10). “Chronic kidney
disease” (CKD) is a general term for heterogenous disorders
affecting kidney function. Current guidelines provide a clas-
siﬁcation of CKD stages on the basis of the estimatedglomerular ﬁltration rate (eGFR): 90 ml/min/1.73 m2
(stage 1), 60 to 89 ml/min/1.73 m2 (stage 2), 45 to 59 ml/
min/1.73 m2 (stage 3a), 30 to 44 ml/min/1.73 m2 (stage 3b),
15 to 29 ml/min/1.73 m2 (stage 4), and <15 ml/min/
1.73 m2 (stage 5) (11). A recent meta-analysis showed a steep
increase in the risk for cardiovascular mortality in a general
population in patients with CKD stage 3 and proposed in
a consensus report the subdivision of CKD stage 3 into
stages 3a and 3b (12,13). Precise pre-screening assessment of
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870CKDstagesmay be a valuable tool
for predicting the risk for mo-
rtality before the procedure. Al-
though some data are available
with respect to the relationship
between CKD stages and clinical
outcomes in the TAVI pop-
ulation, no signiﬁcant relation be-
tween clinical outcomes and the
presence of CKD has been
observed, and increased mortality
rates in patients with advanced
CKD are attenuated after adjust-
ment for other inﬂuential factors
(14,15). The aim of this study was
therefore to elucidate the impact
of detailed CKD classiﬁcation on
clinical outcomes after TAVI.Methods
Patient selection. The study population comprised 661
consecutive patients with symptomatic severe aortic stenosis
who underwent TAVI procedures at 2 French centers.
Patients were selected for TAVI when considered unsuitable
or at high risk for SAVR by consensus between individual
centers and heart team discussion. Operative risk was
calculated using the logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE) and Society of
Thoracic Surgeons predictive risk of mortality score. High
surgical risk was deﬁned as a logistic EuroSCORE >20% or
a Society of Thoracic Surgeons score>10% and according to
the presence of cardiac or noncardiac comorbidities that may
constitute contraindications to surgery or increase sig-
niﬁcantly the surgical risk (16). The eGFR was calculated
using the Modiﬁcation of Diet in Renal Disease (MDRD)
equation: eGFR (ml/min/1.73 m2) ¼ 186  (serum
creatinine)1.154 (age)0.203 (0.742 if female) (17). Patients
were classiﬁed into 4 groups on the basis of eGFR: 60 ml/
min/1.73 m2 (CKD stage 1þ2), 45 to 59 ml/min/1.73 m2
(CKD stage 3a), 30 to 44 ml/min/1.73 m2 (CKD stage 3b),
and 15 to 29 ml/min/1.73 m2 (CKD stage 4) (11). Nineteen
patients receiving regular hemodialysis (CKD stage 5,
eGFR <15 ml/min/1.73 m2) before TAVI were excluded
from the initial analysis because of the statistical instability of
such a small number of patients. The analysis was performed
in the 642 remaining patients. Clinical data, patient char-
acteristics, echocardiographic data, procedural variables,
length of hospital stay, and in-hospital and all-cause
mortality rates were prospectively examined for each group.
Information about the possible occurrence and/or causes of
death was obtained from the treating hospital or by
telephoning directly the patient or the patient’s family. The
medical ethics committees at both hospitals approved this
study protocol, and written informed consent was obtained
from all patients before TAVI.TAVI procedures. TAVI procedures at the 2 centers
have already been described in detail (18–23). Both
commercially available valves were used: the balloon-
expandable Edwards SAPIEN valve (Edwards Lifesciences,
Irvine, California) and the self-expandable Medtronic Cor-
eValve Revalving System (Medtronic Inc., Minneapolis,
Minnesota). The prosthesis size was determined from pre-
procedural echocardiographic and multislice computed
tomographic ﬁndings (19). The devices were delivered via
the femoral, apical, subclavian, transaortic, or transcarotid
route. Criteria for selection of the femoral approach were
based on the size, calciﬁcation, and tortuosity of the aor-
toiliofemoral arterial tree and the ratio between sheath size
and minimal femoral size. The femoral artery was mainly
approached percutaneously using a preclosing technique
(Proster XL, Abbott Laboratories, Inc., Chicago, Illinois)
(20,21,23). The surgical approach was used in instances in
which the femoral route was deemed unsuitable, difﬁcult, or
high risk. Subclavian and carotid access was obtained by
surgical cut-down and closed surgically. The transapical
approach was performed through a left anterior mini-
thoracotomy and the transaortic approach via upper limited
sternotomy. Edwards devices were implanted using mainly
the femoral, apical, or transaortic route. CoreValve devices
were implanted using the femoral, subclavian, or carotid
route (18–23). Among patients with impaired renal function
(eGFR <60 ml/min/1.73 m2), hydration regimens for
reducing the risk for acute kidney injury (AKI) were
administered according to previous recommendations (24):
isotonic 0.9% saline was started at an infusion rate of 1 ml/kg
body weight per hour 12 h before and (continued 12 h) after
TAVI. Procedural success and the 30-day combined safety
endpoint were evaluated according to the Valve Academic
Research Consortium criteria (25). Other procedural
complications during TAVI were also assessed on the basis
of the Valve Academic Research Consortium classiﬁcations.
Statistical analysis. All statistical analyses were performed
using SPSS version 19.0 (SPSS, Inc., Chicago, Illinois).
Continuous variables are expressed as mean  SD or as
medians, depending on variable distribution. Categorical data
are expressed as percents of the total. Comparisons among the
3 age groups were performed using Pearson’s bivariate test
and chi-square tests for categorical covariates and 1-way
analysis of variance for continuous covariates. Prognostic
values of baseline renal function in CKD stages 3a, 3b, and 4
compared with CKD stage 1þ2 as the referent were assessed
using a Cox regression hazard model. A univariate Cox
regression analysis was performed to obtain the hazard ratio
(HR) for 30-day and 1-year mortality after TAVI. There-
after, a multivariate analysis was performed using the variables
with p values<0.20 in the univariate analysis to examine their
independent associations with 30-day and 1-year mortality.
The Kaplan-Meier method was used to estimate cumulative
mortality rates in the 4 groups. Survival differences in each
group were compared using log-rank tests. All statistical tests
were 2 sided, and p values <0.05 were considered signiﬁcant.
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871Results
Baseline patient and procedural characteristics. Of the
642 patients included in this study (mean age 83.5  6.5
years, mean logistic EuroSCORE 22.5  12.2%), 34.0%
were categorized as CKD stage 1þ2 (n ¼ 218), 28.3% as
CKD stage 3a (n ¼ 182), 28.2% as CKD stage 3b
(n ¼ 181), and 9.5% as CKD stage 4 (n ¼ 61). Variations in
baseline characteristics among the 4 study groups resulted in
signiﬁcant differences in the mean logistic EuroSCORE
(18.2% [range: 11.1% to 26.6%] vs. 18.4% [range: 12.1% to
26.9%] vs. 22.2% [range: 16.0% to 30.9%] vs. 24.0% [range:
19.1% to 35.0%], p < 0.001) and Society of Thoracic
Surgeons score (5.0% [range: 3.6% to 7.7%] vs. 6.0% [range:
4.3% to 10.4%] vs. 8.5% [range: 6.3% to 12.2%] vs. 11.0%
[range: 8.7% to 17.7%], p < 0.001) (Table 1). Procedural
characteristics are shown in Table 2. The Edwards valve was
used in 404 patients (62.9%) and the CoreValve in 238
(37.1%). The transfemoral approach was used in 431
patients (67.1%) and nontransfemoral approaches in 211Table 1 Baseline Patient Characteristics
Variable
CKD Stage 1þ2
(n ¼ 218)
CKD Stag
(n ¼ 18
Baseline clinical characteristics
Age (yrs) 80.6  8.1 84.2  5
Men 113 (51.8%) 85 (46.7%
BMI (kg/m2) 27.2  5.0 25.7  4
BSA (m2) 1.80  0.19 1.73  0
NYHA classiﬁcation (III/IV) 166 (76.1%) 143 (78.6%
Peripheral artery disease 72 (33.0%) 50 (27.5%
Prior MI 29 (13.3%) 23 (12.6%
Prior PCI 56 (25.7%) 51 (28.0%
Prior CABG 44 (20.2%) 22 (12.1%
Prior cardiac surgery 53 (24.3%) 21 (11.5%
Prior stroke 21 (9.6%) 17 (9.3%
Diabetes mellitus 57 (26.1%) 33 (18.1%
Hypertension 155 (71.1%) 122 (67.0%
Dyslipidemia 116 (53.2%) 99 (54.4%
Smoking 17 (7.8%) 17 (9.3%
COPD 65 (29.8%) 49 (26.9%
Logistic EuroSCORE (%) 18.2 (11.1–26.6) 18.4 (12.1–
STS score (%) 5.0 (3.6–7.7) 6.0 (4.3–1
eGFR (ml/min/1.73 m2) 80.3  19.5 52.5  4
Creatinine (mg/dl) 0.92  0.22 1.16  0
Echocardiographic data
LVEF (%) 51.7  14.3 51.9  1
Aortic annular diameter (mm) 22.1  2.0 21.6  2
AVA (cm2) 0.67  0.17 0.64  0
Mean gradient (mm Hg) 46.4  17.4 47.3  1
AR grade (0–4) 0.85  0.70 0.82  0
MR grade (0–4) 0.93  0.69 0.90  0
PAP (mm Hg) 47.5  14.0 46.2  1
Post-TAVI AVA (cm2) 1.90  0.54 1.87  0
Post-TAVI mean gradient (mm Hg) 9.0  3.1 8.2  4
Values are mean  SD or n (%).
AR ¼ aortic regurgitation; AVA ¼ aortic valve area; BMI ¼ body mass index; BSA ¼ body surface area
estimated glomerular ﬁltration rate; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluat
NYHA ¼ New York Heart Association; PAP ¼ pulmonary artery pressure; PCI ¼ percutaneous coronary i(32.9%). Although no signiﬁcant differences were observed
in the type of valve, access site, length of hospital stay, and
procedural success rates among the 4 groups, the 30-day
mortality rate and 30-day combined safety endpoint signif-
icantly increased in parallel with CKD severity in the
4 groups (6.9% vs. 8.8% vs. 13.3% vs. 26.2%, p ¼ 0.002, and
14.7% vs. 17.6% vs. 25.4% vs. 31.1%, p ¼ 0.006, respec-
tively). A trend toward a higher incidence of stroke (1.8% vs.
2.7% vs. 4.4% vs. 8.2%, p ¼ 0.084) and AKI (13.3% vs.
14.3% vs. 19.9% vs. 24.6%, p ¼ 0.083) was observed in
parallel with the degree of CKD severity.
Cumulative mortality and baseline renal function. Clin-
ical follow-up was obtained in 100% of patients, with
a median follow-up period of 289 days (interquartile range:
84 to 571 days). A total of 177 patients died; of these,
42 patients were in CKD stage 1þ2, 40 patients in CKD
stage 3a, 56 patients in CKD stage 3b, and 34 patients in
CKD stage 4. Kaplan-Meier analysis of cumulative mortality
in the 4 groups on the basis of renal function is presented ine 3a
2)
CKD Stage 3b
(n ¼ 181)
CKD Stage 4
(n ¼ 61) p Value
.0 85.6  4.3 86.1  5.4 <0.001
) 84 (46.4%) 27 (44.3%) 0.59
.0 25.0  4.2 23.8  3.9 <0.001
.17 1.69  0.18 1.70  0.17 <0.001
) 152 (84.0%) 53 (86.9%) 0.12
) 49 (27.1%) 12 (19.7%) 0.19
) 26 (14.4%) 8 (13.1%) 0.97
) 58 (32.0%) 18 (29.5%) 0.57
) 23 (12.7%) 8 (13.1%) 0.083
) 28 (15.5%) 8 (13.1%) 0.005
) 18 (9.9%) 7 (11.5%) 0.97
) 42 (23.2%) 13 (21.3%) 0.67
) 129 (71.3%) 47 (70.6%) 0.49
) 81 (44.8%) 27 (44.3%) 0.17
) 15 (8.3%) 7 (11.5%) 0.82
) 54 (29.8%) 19 (31.1%) 0.89
26.9) 22.2 (16.0–30.9) 24.0 (19.1–35.0) <0.001
0.4) 8.5 (6.3–12.2) 11.0 (8.7–17.7) <0.001
.6 38.7  4.0 25.5  4.3 <0.001
.23 1.46  0.35 2.10  0.83 <0.001
4.4 50.2  14.2 47.3  14.8 0.12
.4 21.6  2.0 21.6  2.3 0.11
.15 0.62  0.17 0.60  0.16 0.002
57 48.7  18.5 50.0  19.5 0.43
.71 0.85  0.74 0.85  0.78 0.98
.72 0.94  0.68 1.12  0.80 0.32
4.8 50.0  14.8 51.0  14.7 0.054
.48 1.92  0.54 1.81  0.39 0.87
.6 8.3  2.9 10.1  3.5 0.37
; CABG ¼ coronary artery bypass grafting; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼
ion; LVEF ¼ left ventricle ejection fraction; MI ¼ myocardial infarction; MR ¼ mitral regurgitation;
ntervention; STS ¼ Society of Thoracic Surgeons; TAVI ¼ transcatheter aortic valve implantation.
Table 2 Procedural Patient Characteristics
Variable
CKD Stage 1þ2
(n ¼ 218)
CKD Stage 3a
(n ¼ 182)
CKD Stage 3b
(n ¼ 181)
CKD Stage 4
(n ¼ 61) p Value
Type of valve
CoreValve 85 (39.0%) 69 (37.9%) 64 (35.4%) 20 (37.1%) 0.78
Edwards SAPIEN 133 (61.0%) 113 (62.1%) 117 (64.6%) 41 (67.2%)
Approach route
Transfemoral 141 (64.7%) 115 (63.2%) 134 (74.0%) 41 (67.2%) 0.12
Nontransfemoral 77 (35.3%) 67 (36.8%) 47 (26.0%) 20 (32.8%)
Procedural variables
Procedure time (min) 85.4  36.4 89.1  54.5 87.5  44.4 101.6  52.7 0.23
Fluoroscopy time (min) 18.8  10.4 17.9  9.4 20.3  13.3 20.4  9.5 0.36
Contrast medium volume (ml) 165.2  87.3 152.1  68.5 159.4  64.9 139.6  76.2 0.13
Post-procedural variables
Length of hospital stay (days) 10.1  6.2 11.3  7.9 11.4  10.5 9.7  6.4 0.24
Procedural success 205 (94.0%) 167 (91.8%) 165 (91.2%) 54 (88.5%) 0.49
30-day mortality 15 (6.9%) 16 (8.8%) 24 (13.3%) 14 (23.0%) 0.002
30-day combined safety endpoint 32 (14.7%) 32 (17.6%) 46 (25.4%) 19 (31.1%) 0.006
Procedural MI 1 (0.5%) 2 (1.1%) 0 (0.0%) 0 (0.0%) 0.44
Major stroke 4 (1.8%) 5 (2.7%) 8 (4.4%) 5 (8.2%) 0.084
AKI grade 2 29 (13.3%) 26 (14.3%) 36 (19.9%) 15 (24.6%) 0.083
AKI grade 3 2 (0.9%) 2 (1.1%) 3 (1.7%) 3 (4.9%) 0.15
Need for dialysis at discharge 2 (0.9%) 1 (0.5%) 1 (0.6%) 0 (0.0%) 0.87
Major vascular complications 16 (7.3%) 15 (8.2%) 15 (8.3%) 6 (9.8%) 0.93
RBC transfusion 46 (21.1%) 46 (25.3%) 47 (26.0%) 18 (28.5%) 0.48
RBC transfusion 4 U 18 (8.3%) 15 (8.2%) 15 (8.3%) 3 (4.9%) 0.84
Pacemaker implantation 19 (8.7%) 24 (13.2%) 19 (10.5%) 4 (6.6%) 0.37
2 valves implanted 5 (2.3%) 6 (3.3%) 6 (3.3%) 0 (0.0%) 0.50
Post-TAVI AR grade 2 43 (19.7%) 44 (24.2%) 46 (25.4%) 19 (31.1%) 0.25
Need for any cardiac surgery 4 (1.8%) 6 (3.3%) 5 (2.8%) 4 (6.7%) 0.28
Need for vascular surgery 9 (4.1%) 9 (4.9%) 6 (3.3%) 3 (4.9%) 0.88
Values are n (%) or mean  SD.
AKI ¼ acute kidney injury; RBC ¼ red blood cell; other abbreviations as in Table 1.
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872Figure 1. Cumulative 1-year and 2-year mortality rates in
each individual group were 17.2%, 23.4%, 29.2%, and 47.8%,
respectively, and 25.5%, 28.8%, 36.8%, and 68.2%, respec-
tively. The probability of cumulative mortality over the entire
follow-up period after TAVI was similar between CKD stage
1þ2 and CKD stage 3a (p ¼ 0.52). In contrast, the mortality
rates of CKD 3b and 4 were signiﬁcantly higher in
comparison with CKD stage 1þ2 as the referent (p ¼ 0.016
and p < 0.001, respectively). The cumulative 30-day (early)
and 30-day to 730-day (late) mortality in the 4 groups is also
given in Figure 2. Cumulative early and late mortality rates in
each individual group were 6.9%, 8.8%, 13.3%, and 23.0%,
respectively, and 19.9%, 21.9%, 29.4%, and 58.7%, respec-
tively. A trend toward a higher incidence of late mortality was
observed in patients with CKD stage 3b (p ¼ 0.09), and
a signiﬁcant increment was observed in patients with CKD
stage 4 (p < 0.001) compared with CKD stage 1þ2.
Prognostic value of baseline renal function after
TAVI. The Cox regression analysis for the association
between clinical outcomes and CKD classiﬁcation is shown in
Table 3. Predictive factors of overall mortality were assessed
using a Cox regression hazard model. CKD stage 3b, CKD
stage 4, and logistic EuroSCORE (per 1% increase) were
associated with poor prognosis at 30 days. Of these, CKDstage 4 (HR: 3.04; 95% conﬁdence interval [CI]: 1.43 to 6.49;
p ¼ 0.004) and logistic EuroSCORE (HR: 1.03; 95% CI:
1.00 to 1.05; p ¼ 0.028) were independently associated with
increased risk for 30-day mortality in the multivariate model.
In the univariate analysis, HR for CKD stage 3b, CKD stage
4, New York Heart Association classiﬁcation (III or IV), prior
stroke, chronic obstructive pulmonary disease, left ventricular
ejection fraction (per 1% increase), and logistic EuroSCORE
were signiﬁcant predictors of 1-year mortality. The multi-
variate Cox regression model indicated impaired renal func-
tion as CKD stage 3b (HR: 1.71; 95% CI: 1.09 to 2.68;
p ¼ 0.020), CKD stage 4 (HR: 2.91; 95% CI: 1.73 to 4.90;
p < 0.001), and logistic EuroSCORE (HR: 1.02; 95% CI:
1.01 to 1.03; p¼ 0.009) as the only independent predictors of
1-year mortality (Table 4).Discussion
The present study demonstrates that CKD classiﬁcation
provides useful information for predicting early and midterm
clinical outcomes in patients undergoing TAVI. Although
the 30-day and 1-year outcomes of patients with CKD stage
1þ2 and CKD stage 3a (eGFR 45 ml/min/1.73 m2)
seemed to be similar, CKD stage 4 (eGFR 15 to 29 ml/min/
Figure 1 Time-to-Event Curves for Cumulative Mortality
Mortality rate was calculated using Kaplan-Meier methods and compared using the log-rank test according to chronic kidney disease (CKD) classiﬁcation. TAVI ¼ transcatheter
aortic valve implantation.
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8731.73 m2) was associated with increased 30-day mortality,
and CKD stage 3b (eGFR 30 to 44 ml/min/1.73 m2) and
stage 4 were associated with increased cumulative 1-year
mortality without attenuation after adjusting for confound-
ing variables. A trend toward a higher incidence of late (from
30 to 730 days) mortality was also observed in patients with
CKD stage 3b (p ¼ 0.09), and a signiﬁcant increment
was observed in patients with CKD stage 4 (p < 0.001)
compared with CKD stage 1þ2. In particular, CKD stage 4
was associated with very high 30-day (26.2%) and 1-year
(47.8%) mortality rates. The cutoff value of eGFR < 30
ml/min/1.73 m2 may be considered the threshold for pre-
dicting early mortality and eGFR <45 ml/min/1.73 m2 the
threshold for predicting midterm mortality.
Assessment of baseline renal dysfunction is clinically
important in patients undergoing TAVI, as it is associated
with an increased risk for adverse events (8,26). Whereas
previous renal dysfunction criteria were limited given that
they were established on an individual basis using mainly
serum creatinine values, CKD classiﬁcation, in contrast, is
a global concept that reﬂects heterogenous disorders af-
fecting kidney function. To date, there have been only a few
reports focusing on CKD staging in relation to clinical
outcome in TAVI cohorts (14,15). The ﬁrst report did not
reveal any increase in the mortality rate of patients with
CKD (eGFR <60 ml/min/1.73 m2) compared with those
without CKD (14). The second report showed a higher
incidence of cardiovascular death in patients with advancedCKD (eGFR 30 to 59 and 15 to 29 ml/min/1.73 m2),
although this difference was not found to be signiﬁcant
by multivariate analysis (15). Published guidelines have
provided a classiﬁcation of CKD stages into several cate-
gories according to the eGFR (11). A recent meta-analysis
revealed a steep rise in the risk for cardiovascular mortality
in advanced CKD groups of a general population and sug-
gested that CKD stage 3 (eGFR 30 to 59 ml/min/1.73 m2)
should be divided into stages 3a and 3b using a threshold
eGFR of 45 ml/min/1.73 m2 for each CKD staging
assessment (12,13). Consequently, because of the larger
number of patients compared with previous reports, our
study identiﬁed signiﬁcant prognostic differences on the
basis of the subdivided CKD classiﬁcation. The threshold of
eGFR <60 ml/min/1.73 m2 was considered an indicator of
moderate to severe damage in kidney function (11) in
patients generally designated as having CKD. However, in
high-risk elderly TAVI patients, the present results may
suggest that eGFR <45 ml/min/1.73 m2 as the optimal
cutoff value has better predictive accuracy with respect to
late adverse clinical outcomes.
The 30-day and cumulative 1-year mortality rates in the 4
study groups were 6.9%, 8.8%, 13.3%, and 26.2%, respec-
tively, and 17.2%, 23.4%, 29.2%, and 47.8%, respectively. In
addition, cumulative 2-year mortality of patients with stage 4
CKD was 68.2%. Cohort B of the pivotal Placement of
Transcatheter Aortic Valves study was designed to compare
the clinical outcomes of patients considered inoperable for
Figure 2 Time-to-Event Curves for Cumulative Early (30-Day) and Late (30-Day to 730-Day) Mortality
Mortality rate was calculated using Kaplan-Meier methods and compared using the log-rank test according to chronic kidney disease (CKD) classiﬁcation. TAVI ¼ transcatheter
aortic valve implantation.
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874SAVR who were randomized to TAVI versus medical
treatment (27). The 30-day and 1-year all-cause death rates
were 5.0% and 30.7% in the TAVI group and 2.8% and
50.7% in the medical group (27). The 2-year follow-upTable 3 Cox Regression Analysis for the Association Between 30-Da
Variable
Univariate A
HR 95% CI
Baseline renal function
CKD stage 1þ2 (eGFR >60 ml/min/1.73 m2) 1.00
CKD stage 3a (eGFR 45–60 ml/min/1.73 m2) 1.30 0.64–2.62
CKD stage 3b (eGFR 30–45 ml/min/1.73 m2) 2.00 1.05–3.81
CKD stage 4 (eGFR <30 ml/min/1.73 m2) 3.63 1.75–7.52
Adjusting factors
Age (per 1-yr increase) 1.01 0.98–1.05
Male 1.06 0.66–1.69
BSA (per 0.1-m2 increase) 0.55 0.15–1.93
NYHA classiﬁcation (III/IV) 1.93 0.93–4.04
Peripheral artery disease 1.10 0.66–1.83
Prior MI 1.53 0.84–2.80
Prior cardiac surgery 1.62 0.94–2.80
Prior stroke 1.78 0.94–3.40
Diabetes mellitus 0.79 0.52–1.21
COPD 1.31 0.80–2.14
LVEF (per 1% increase) 0.99 0.97–1.01
Pulmonary hypertension (>60 mm Hg) 0.81 0.44–1.48
Logistic EuroSCORE (per 1% increase) 1.03 1.01–1.05
Valve type (CoreValve) 0.68 0.40–1.14
Approach route (transfemoral) 0.75 0.47–1.22
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.results showed a very high mortality rate in the medical
group (68.0%) (28). We observed similar 1-year and 2-year
death rates in patients with CKD stage 4 after TAVI, but we
were unable to extrapolate what would have been the 2-yeary Cumulative Mortality and Clinical Findings
nalysis Multivariate Analysis
p Value HR 95% CI p Value
1.00
0.47 1.37 0.67–2.78 0.39
0.035 1.82 0.94–3.50 0.074
0.001 3.04 1.43–6.49 0.004
0.49
0.82
0.35
0.080 1.63 0.77–3.45 0.21
0.72
0.17 1.32 0.71–2.44 0.38
0.085 1.37 0.76–2.45 0.30
0.078 1.51 0.78–2.90 0.22
0.28
0.29
0.21
0.49
0.001 1.03 1.00–1.05 0.028
0.14 0.75 0.44–3.45 0.21
0.25
Table 4 Cox Regression Analysis for the Association Between 1-Year Cumulative Mortality and Clinical Findings
Variable
Univariate Analysis Multivariate Analysis
HR 95% CI p Value HR 95% CI p Value
Baseline renal function
CKD stage 1þ2 (eGFR >60 ml/min/1.73 m2) 1.00 1.00
CKD stage 3a (eGFR 45–60 ml/min/1.73 m2) 1.35 0.84–2.16 0.22 1.34 0.83–2.15 0.23
CKD stage 3b (eGFR 30–45 ml/min/1.73 m2) 1.86 1.19–2.89 0.006 1.71 1.09–2.68 0.020
CKD stage 4 (eGFR <30 ml/min/1.73 m2) 3.54 2.14–5.85 <0.001 2.91 1.73–4.90 <0.001
Adjusting factors
Age (per 1-yr increase) 1.01 0.98–1.04 0.33
Male 1.30 0.94–1.81 0.11 1.24 0.88–2.31 0.15
BSA (per 0.1-m2 increase) 0.86 0.36–2.05 0.74
NYHA classiﬁcation (III/IV) 1.63 1.02–2.62 0.042 1.43 0.88–2.31 0.15
Peripheral artery disease 1.22 0.86–1.73 0.26
Prior MI 1.30 0.82–2.04 0.26
Prior cardiac surgery 1.16 0.77–1.77 0.48
Prior stroke 1.72 1.08–2.73 0.022 1.59 0.99–2.55 0.052
Diabetes mellitus 0.79 0.52–1.21 0.28
COPD 1.49 1.06–2.08 0.021 1.36 0.96–1.91 0.082
LVEF (per 1% increase) 0.99 0.98–0.99 0.025 0.99 0.98–1.01 0.71
Pulmonary hypertension (>60 mm Hg) 1.11 0.77–1.63 0.57
Logistic EuroSCORE (per 1% increase) 1.03 1.02–1.04 <0.001 1.02 1.01–1.03 0.009
Valve type (CoreValve) 0.81 0.57–1.15 0.23
Approach route (transfemoral) 0.81 0.58–1.13 0.22
Abbreviations as in Tables 1 and 3.
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875mortality rate of these patients if they had been treated
medically.
Patients with hemodialysis were excluded from the anal-
ysis of this study. Operative mortality rates after SAVR
among hemodialysis patients have been reported to be
between 10% and 35% and 1-year mortality rates between
20% and 45% (29–32). These results translate into a very
poor outcome, which is, nevertheless, comparable with that
observed in patients with CKD stage 4 undergoing TAVI.
In view of these data, TAVI for dialysis patients may
represent a signiﬁcant challenge, and a large-scale analysis
would be warranted to clarify the clinical outcomes of dial-
ysis patients undergoing TAVI.
In the present report, we have highlighted trends toward
higher incidence of major stroke and AKI in patients with
advanced-stage CKD. When dividing the patients into 2
groups with an eGFR cutoff of 45 ml/min/1.73 m2, the
incidences of major stroke, AKI grade 2 and AKI grade 3
complications are signiﬁcantly higher in the low-eGFR
group (2.3% vs. 5.4%, p ¼ 0.035, 13.8% vs. 21.1%,
p ¼ 0.015, and 1% vs. 3.3%, p ¼ 0.037, respectively). Both
procedural stroke and AKI have been shown to be signiﬁcant
predictors of higher mortality rates after TAVI (8,33–36).
The mechanisms of procedural stroke were multifactorial and
were triggered by multiple factors, such as cerebral embolism
of aortic valve tissue, atherosclerotic debris embolization from
the aorta, and ischemic hypoperfusion brain damage during
the procedure (33). The occurrence of AKI was also associ-
ated with several causes other than baseline renal function
(36), which presented as advanced CKD class in our study,but also hypertension or need for red blood cell transfusion
(35). In addition, we have shown recently that the amount of
contrast media is associated with increased risk for AKI after
TAVI (37). Thus, efforts to reduce the contrast media dose
during screening and TAVI procedures should be consid-
ered, especially in patients with impaired renal function.
Although the best solution to prevent these complex
complications has not been clearly identiﬁed, further thera-
peutic considerations and device reﬁnements are necessary in
these high-risk patients.
Study limitations. We report a prospective multicenter
TAVI cohort of a relatively moderate number of patients,
which is too limited in size to allow us to deﬁne the optimal
cutoff value of eGFR and CKD classiﬁcation. A median
follow-up duration of 289 days is insufﬁcient. The calcula-
tion of eGFR using the MDRD equation in elderly patients
is limited in terms of reliability, as is the Cockcroft-Gault
method (38), although these methods proved superior to
serum creatinine for estimating renal function. We should
consider the fact that eGFR deﬁned using the MDRD
formula in the elderly is affected by the considerable decline
in muscle mass with age, as well as by drugs and diet. Even if
several formulas are commonly used as surrogates of the
patients’ glomerular ﬁltration rates across all ages, few
participants age >80 years have been enrolled in the studies
that evaluated the reliability of these formulas. The serial
change in renal function is clinically important especially in
the group of impaired renal function after TAVI. However,
these informative data were not available in our study. The
direct causes of death may be difﬁcult to determine in
Yamamoto et al. JACC Vol. 62, No. 10, 2013
Prognostic Value of CKD in TAVI Patients September 3, 2013:869–77
876a cohort of elderly patients and were, consequently, not
always clearly identiﬁed in this study.
Conclusions
The results of our study suggest that CKD classiﬁcation
could be a useful tool for potential risk stratiﬁcation before
TAVI. Indeed, dividing TAVI candidates into CKD cate-
gories may be clinically important for risk assessment with
a view to ensuring optimal TAVI management in patients
with advanced-stage CKD.
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